VEGF-C gene therapy - Herantis Pharma

Drug Profile

VEGF-C gene therapy - Herantis Pharma

Alternative Names: Ad-VEGF-C - Herantis Pharma; Lymfactin

Latest Information Update: 25 Jan 2017

Price : $50

At a glance

  • Originator University of Helsinki
  • Developer Herantis Pharma
  • Class Gene therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factor C expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Lymphoedema

Most Recent Events

  • 23 Jan 2017 Herantis Pharma has patent protection for VEGF-C gene therapy
  • 01 Jun 2016 Phase-I clinical trials in Lymphoedema in Finland (Parenteral) (9210605; NCT02994771)
  • 19 Jan 2016 Herantis Pharma plans a phase I trial for Lymphema in Europe (company pipeline; January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top